Press Room

Event

CRS 2026 Annual Meeting

Start
Monday, July 06, 2026
End
Thursday, July 09, 2026
Location: Lisbon, Portugal

Hovione is presenting at the CRS 2026 Annual Meeting, taking place in Lisbon, Portugal. The conference will explore groundbreaking advancements and transformative ideas in controlled release science and technology. Join the Hovione team for an inspiring week of insightful presentations, engaging discussions, and unparalleled networking opportunities with leading experts and innovators from around the world. 

Schedule a meeting. Let’s discuss your project together.

schedule a meeting
https://go.hovione.com/l/47122/2014-08-06/9grc

Don’t miss the chance to speak with our experts and learn how we are advancing a differentiated offering in Biologics and Complex Injectables, from early development through to cGMP supply. 

HOVIONE TECHNICAL FORUM

Rational Formulation Strategies for High Concentration Subcutaneous Biologics: From Innovative Excipients to Spray Dried Drug Product Suspensions

July 7, 9:00–10:00 AM (WEST)

Joana Cristóvão, Ph.D. | R&D, Analytical Senior Manager
Inês Matos, Ph.D.| R&D, Inhalation & Advanced Drug Delivery Manager

Innovative formulation and manufacturing strategies are accelerating the shift from intravenous (IV) to patient-friendly subcutaneous (SC) delivery of biologics. This transition is driven by strong patient preference, reduced healthcare burden, and the opportunity for at-home administration. But challenges remain, especially for high-dose biologics. 

At the Hovione Technical Forum, in a single session, two complementary presentations will showcase how advanced formulation science and particle engineering are expanding the possibilities for efficient, scalable, and patient-centric biologic therapies:

  • Learn more about novel excipient design strategies to reduce viscosity and enhance stability in high-concentration liquid formulations
  • Get insights on spray drying as an enabling technology for biologics, unlocking new solid-state and ultra-concentrated formats

ORAL PRESENTATION

Addressing Nasal Delivery Challenges: Integrated Formulation and Device Strategies for Predictive Performance

July 8, 2:53 PM - 3:16 PM WEST

Patrícia Henriques, Ph.D. | Scientist, Inhalation and Advanced Drug Delivery

POSTERS & Poster Presenter

  • (113) Looking Beyond Aerodynamics: Evaluation of Fluticasone Furoate via Dissolution and Permeation using Lung ALIs 
    Beatriz Gamelas, M.Sc.| Ph.D. Candidate, Analytical Development
     
  • (132) Why Model Structure Matters: Translatability Across Inhalation PBPK Frameworks 
    Filipa Ferreira, Pharm.D., Ph.D. | Senior Scientist II, Translational Lead | Innovation
     
  • (502) Innovative Synthetic Sugars for Stable, Low-viscosity High-Concentration Biologic Formulations
    Joana Cristóvão, Ph.D. | R&D, Analytical Senior Manager
     
  • (655) Optimizing CRISPR/Cas9 Polymeric Nanoparticle Formulations: From In Silico Insights to Microfluidics and Stability Strategies
    Andreia Sofia Pereira | Student, Inhalation and Advanced Drug Delivery
     
  • (655) CRISPR/Cas9 Nanoparticle Formulations: From In Silico Insights to Microfluidics and Stability Strategies
schedule a meeting
https://go.hovione.com/l/47122/2014-08-06/9grc

Ask us how we’re advancing more patient centric therapies through proprietary excipients, such as synthetic sugars, and spray dried approaches that unlock alternative dosage forms.

 

 

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping
News Medical Life Sciences, 1 June 2026

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026

Every year, the largest bank in Portugal, Caixa Geral de Depósitos recognizes some of Portugal’s brightest young minds through the Caixa +Mundo Awards, providing nearly €800,000 in scholarships to students as they pursue higher education. In this year´s edition, Caixa named the award bestowed upon students pursuing science for Diane Villax. This prestigious honor places Diane Villax among the award’s namesakes – a distinguished group of prominent personalities who have made notable contributions to Portugal´s socio-economic, cultural, political and scientific development over the last 50 years, such as António Ramalho Eanes, Mário Soares, José Saramago, Sophia de Mello Breyner, Leonor Beleza, Elvira Fortunato, Rui Nabeiro, Américo Amorim, and José Manuel de Mello. Diane Villax will also honor the seven scientific award winners by personally meeting with each of them, and following their journeys as future innovators and leaders. But this honor is about far more than one individual. It is a celebration of an entire organization and the people behind it. For 67 years, generations of dedicated teams have worked together with passion, purpose, and excellence to manufacture life-saving medicines and advance science that has a real impact on people. This recognition belongs to all of us.    

News

Prestigious Caixa +Mundo Award named in honor of Diane Villax

May 14, 2026

CDMO Hovione and Industrial Design Consultancy (IDC) have announced that their new single-use capsule-based nasal delivery device is now available exclusively as part of an integrated platform that includes Hovione’s intranasal drug development and manufacturing services. The companies partnered in 2023 with plans for development of two capsule-based devices for intranasal delivery: the single-use device and a multidose device. Read the full article at OINDPnews.com      

Press Clipping
OINDP - Orally inhaled and nasal drug products news, May 11, 2026

Hovione and IDC announce new single-use capsule-based intranasal delivery device for dry powder formulations

May 11, 2026

Also in Events

See All